Enveric Biosciences, a leading psychedelics biotech company, has presented promising preclinical research on its lead compound EB-003, a non-hallucinogenic DMT analog, at the 7th Neuropsychiatric Drug Summit. The research suggests that EB-003 could be a potential treatment for anxiety and depression, showing positive behavioral outcomes in mouse models.
Irish psychedelic biotech firm GH Research PLC (GHRS) reported its second-quarter financial results, highlighting a net loss of $10.4 million but significant progress in clinical trials for its DMT-related drug candidates. The company is investigating two mebufotenin-based products for treatment-resistant depression.
In Colorado Springs, a unique gathering space has emerged – a psychedelic church where individuals can explore spirituality, community, and the therapeutic potential of psychedelics. Founded by Benji ‘Dez’ Dezaval, who believes in the healing power of substances like psilocybin mushrooms and DMT, the church operates within the legal framework of Colorado’s decriminalized psychedelic landscape. Offering a safe and educational environment, the church welcomes individuals from diverse backgrounds, fostering connection and challenging stigmas surrounding psychedelics.
